- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Durvalumab Combined Chemotherapy Extends OS in Advanced Biliary Tract Cancer
January 20, 2022
TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.
FDA Grants Fast Track Designation to Gedatolisib for HR+/HER2- mBC
January 20, 2022
Gedatolisib has earned attention from the FDA after demonstrating encouraging efficacy and safety in a phase 1b clinical trial.
New EGFR-Targeted Therapies Enter the NSCLC Landscape
January 20, 2022
Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.
Doctors Debate: Should Stage III Melanoma Be Treated in the Adjuvant or Neoadjuvant Setting?
January 20, 2022
During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.
Zanubrutinib May Fill the Treatment Gap for CLL With Deletion 17p
January 19, 2022
In an interview with Targeted Oncology, Jennifer Brown, MD, PhD discussed the early analysis of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia and deletion 17p.
Approaches and Obstacles to Frontline Treatment for Small Cell Lung Cancer
January 19, 2022
During a live virtual event, Melissa L. Johnson, MD, discussed how to treat a 73-year-old patient who was recently diagnosed with extensive-stage small cell lung cancer.
Cervical Cancer Awareness Month: Trials Assess New Immunotherapies
January 19, 2022
Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.
FDA to Review sBLA for Frontline Cemiplimab Plus Chemotherapy in Advanced NSCLC
January 19, 2022
The FDA is reviewing a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy as a first-line treatment option for patients with advanced non-small cell lung cancer.
Few Patients With ICI-Mediated Mucositis Require Immunosuppression
January 19, 2022
Retrospective data show that only 24% of patients treated with immune checkpoint inhibitors required immunosuppression while the rest recovered over time.
Cinrebafusp Alfa Combinations Explored in HER2-Expressing Gastric Cancer
January 18, 2022
A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.
Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC
January 18, 2022
Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.
Idelalisib for Relapsed FL and SLL Voluntarily Withdrawn from US Market
January 18, 2022
Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.